A simple sponge-on-a-string device called Cytosponge, developed by this research team, is already being rolled out in the NHS to catch pre-cancerous changes in people with heartburn. The problem is that oesophageal and stomach cancers are often diagnosed too late—fewer than 20% of patients survive beyond five years, and rates in the UK have risen six-fold in the past 30 years. This research aims to understand why mutations accumulate in the cells lining the oesophagus and stomach, and whether these cancers arise from one cell type or several distinct subtypes with different prognoses. If successful, the team will build clinical prediction models that can tell which patients with Barrett’s oesophagus will develop aggressive cancer and which will not. They plan to apply these models directly to Cytosponge samples and combine them with advanced endoscopy imaging. The ultimate goal is to feed these tools into clinical trials, shifting management from late-stage treatment to early, targeted prevention—a change that could quietly reshape how the NHS screens and monitors a common, deadly cancer.
View original technical description
Cancers of the gullet (oesophagus) and at the junction with the stomach are the sixth most common cause of cancer mortality worldwide. In the UK rates of this cancer type have increased 6-fold in the past 30 years and the outcomes are poor with fewer than 20% living beyond 5 years because of late diagnosis. On the other hand, there is the opportunity to detect these cancers early and prevent progression to life-threatening disease because they develop gradually from pre-cancerous stages over a period of years. One example of our work to date has been the development of the Cytosponge sampling device and laboratory test (called TFF3) which can be given to patients with heartburn, who are at risk of the pre-cancerous condition Barrett's oesophagus. Cytosponge is now CE marked and commercially available with compelling clinical trial data to support its use and plans for NHS implementation. The key aims in the next five years are to better understand why mutations accumulate in cells of the oesophagus and stomach that make cancer more likely to develop. We would like to understand whether there is more than one cell of origin for the development of these cancers or whether it is one type of disease with different sub-types that each have a different prognosis. We will develop clinical prediction models to determine whether patients with Barrett's are likely to have an indolent or an aggressive path and then apply this to Cytosponge samples and incorporate sophisticated endoscopy imaging techniques. The Fitzgerald group is highly collaborative and includes clinicians and scientists with a range of expertise. We are ideally placed to translate our findings into clinical trials through the nearby Clinical Research Facility with state-of-the-art endoscopy equipment. In summary, we plan an ambitious programme that will provide a bridge to clinical trials to improve management strategies for this aggressive cancer.
Plain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research.
Is something wrong? Let us know